Novo, Hims End GLP-1 Feud, Partner Again on Wegovy

In a surprising turn in the competitive world of GLP-1 medications for obesity, Novo Nordisk and Hims & Hers Health are set to announce a renewed partnership. This Novo Nordisk Hims partnership will allow the Danish drugmaker to sell its blockbuster weight-loss drug Wegovy directly through Hims' telehealth platform, effectively ending a months-long feud. Bloomberg's late Friday report highlights how this move comes just after Novo sued Hims over copycat GLP-1s, signaling a pragmatic shift amid market pressures.

The Bloomberg Report: Details of the Novo-Hims Partnership

Bloomberg published the report late Friday, citing a person familiar with the matter: "Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.'s platform." The two companies plan to announce the new partnership as soon as Monday. This echoes a similar agreement from last year, which Novo abruptly scrapped after Hims refused to stop marketing and selling copycat medications.

GLP-1 receptor agonists like Wegovy (semaglutide) mimic the GLP-1 hormone to regulate blood sugar, slow gastric emptying, and reduce appetite, leading to significant weight loss—often 15-20% of body weight in clinical trials. Telehealth platforms like Hims have exploded in popularity for obesity treatment, offering convenient access to prescriptions, consultations, and compounded alternatives amid supply shortages of branded drugs.

Why Telehealth Matters for GLP-1 Access

With Wegovy's high demand, partnerships like this expand distribution beyond traditional pharmacies. Hims' model—virtual doctor visits, home delivery—lowers barriers for patients in rural areas or those avoiding in-person stigma. However, regulatory scrutiny on compounded GLP-1s (non-FDA-approved copies) has intensified, making authentic branded sales a safer bet for both companies.

Background on the GLP-1 Feud Between Novo and Hims

The feud escalated last month when Novo sued Hims over a copycat Wegovy pill and patent infringement tied to Ozempic and Wegovy. Even the head of the FDA recently stated that telehealth firms were put on notice about copycat GLP-1s. This legal clash stemmed from Hims' aggressive push into compounded semaglutide, which undercut Novo's pricing but raised safety concerns due to variability in compounding quality.

Previously, Novo and Hims had a partnership allowing Wegovy sales on the platform, but Novo ended it when Hims persisted with copycats. The surprise reconciliation suggests negotiations prioritized mutual growth over litigation in a market where GLP-1 drugs generated over $20 billion globally last year.

Stock Market Reaction to the Feud's End

The news triggered immediate market enthusiasm. NOVO ADRs rose 2% in after-hours trading on Friday, while HIMS shares surged nearly 40%. Leerink Partners analyst Michael Cherny described the Hims news as "both a surprise and an unabashed positive for Hims' stock" in a note to clients.

Hims' float is 39.65% short, or 81 million shares, amplifying the short squeeze potential. Novo's stock has faced a terrible year-to-date performance, as has Hims', fueling the urgency for positive catalysts.

Analyst Insights on the Strategic Shift

Cherny added, "We get the rationale for Novo here. The company has been looking to add as many partners as it can to drive market reach, including other digital pharmacies and CVS." This aligns with Novo's broader strategy to combat competition from Eli Lilly's Zepbound (tirzepatide) and emerging oral GLP-1s.

Also this week, Novo's biggest bull, Goldman analyst James Quigley, downgraded the stock from "Buy" to "Hold." The full note is available to pro subscribers, but it reflects dismal outlooks amid the highly competitive obesity space. The rationale for the feud's end will likely be detailed by Novo and Hims executives on Monday, if the report holds.

Pressures Driving Novo's Partnership Decision

Novo's new GLP-1 pill has yet to reverse its multi-year stock plunge or gain sufficient market share. The new CEO faces investor pressure to offer hope amid a challenging year. Partnering with Hims again broadens reach without the costs of ongoing lawsuits, especially as telehealth captures a growing share of prescriptions—projected to hit 30% of obesity treatments by 2025.

Competitive Landscape in Obesity Drugs

The obesity market is fierce: Wegovy competes with Zepbound, which showed superior weight loss in head-to-head trials. Supply constraints have pushed patients to telehealth for alternatives, but FDA crackdowns on unapproved compounds favor branded partnerships like this one.

What This Means for Patients Seeking GLP-1 Therapy

For patients, this partnership simplifies access to authentic Wegovy via Hims' user-friendly platform—no more navigating shortages or risky compounds. Discuss with your doctor if GLP-1s suit you, especially with cardiovascular risks (Ozempic/Wegovy also reduce heart events by up to 20% per SELECT trial data). Common side effects include nausea, GI issues—tools like Shotlee can help track symptoms and schedules for better adherence.

Who benefits most? Those with BMI ≥30 or ≥27 with comorbidities like hypertension. Always prioritize FDA-approved options; consult providers about dosing (Wegovy starts at 0.25mg weekly, titrating to 2.4mg).

Safety Considerations with GLP-1 Medications

• Gastrointestinal effects: Nausea (44%), diarrhea (30%)—usually transient.
• Rare risks: Pancreatitis, gallbladder issues; monitor thyroid history.
• Long-term: Muscle loss risk—pair with resistance training, protein-rich diet.

Telehealth partnerships enhance monitoring via apps, but in-person check-ins remain key.

Key Takeaways from the Novo-Hims GLP-1 Partnership

• Feud ends with Wegovy sales on Hims platform, announcement possibly Monday.
• Follows scrapped prior deal, lawsuit over copycats, FDA warnings.
• Stocks surge: Hims 40%, Novo 2%; high short interest on Hims.
• Novo seeks partners for reach amid competition, CEO pressures.
• Patients gain easier branded GLP-1 access via telehealth.

Conclusion: A Pragmatic Win in GLP-1 Wars

The Novo Nordisk and Hims & Hers partnership marks a detente in GLP-1 tensions, prioritizing expansion over enmity. Watch Monday's announcements for full details. For patients, it promises broader Wegovy availability—talk to your healthcare provider about integrating GLP-1s into metabolic health plans. Stay informed on evolving telehealth regs and market dynamics for optimal obesity management.